Business
Propanc Biopharma Receives First Allowance for Key Patent Family from Australian Patent Office
Allowed Claims Capture Different Dosage Regimens to be the Focus of Ongoing Research MELBOURNE, Australia--(BUSINESS WIRE)-- Propanc Biopharma, Inc.
About this update from Propanc Biopharma, Inc.
[{"type":"text","content":"\nAllowed Claims Capture Different Dosage Regimens to be the Focus of Ongoing Research\n\n MELBOURNE, Australia--(BUSINESS WIRE)--\nPropanc Biopharma, Inc. (OTC:PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing new cancer treatments for patients suffering from recurring and metastatic cancer, announced today that the first allowance for an important patent family was received from the Australian Patent Office. The allowed claims capture different dosage regimens, including those to be the focus of ongoing research, as the Company’s lead product candidate, PRP, advances towards clinical trials for the treatment of patients with advanced solid tumors.\n\n\nThe key patent application, citing proenzyme compositions, is one of four patent families, consisting of 65 patents either in force or pending, and is the first to be allowed covering high doses of two proenzymes trypsinogen and chymotrypsinogen for the treatment of cancer. As a result, examination of patent applications in a number of other jurisdictions can be expedited where the Australian claims will be utilized for supplementary examination.\n\n\n“The approval of this key patent application in Australia is a significant step forward for our intellectual property portfolio and is especially important as we prepare for entering the clinic in Australia,” said James Nathanielsz, Propanc’s Chief Executive Officer.\n\n\nDr Julian Kenyon, Propanc’s Chief Scientific Officer said, “The aim of our first clinical trial will be to identify the maximum tolerated dose patients with advanced solid tumors, knowing that we continue to expand our intellectual property portfolio as a world first in the cancer field using a novel proenzyme treatment approach, helps build confidence that we are on track with our research.”\n\n\nAbout Propanc Biopharma, Inc.\n\n\nPropanc Biopharma, Inc. (the “Company”) is developing a novel approach to prevent recurrence and metastasis of solid tumors by using pancreatic proenzymes that target and eradicate cancer stem cells in patients suffering from pancreatic, ovarian and colorectal cancers. For more information, please visit www.propanc.com.\n\n\nThe Company’s novel proenzyme therapy is based on the science that enzymes stimulate biological reactions in the body, especially enzymes secreted by the pancreas. These pancreatic enzymes c...